Roche has announced that the Russian Ministry of Health has broadened the indications for Alectinib, now approved for use as adjuvant therapy in patients with ALK-positive non-small cell lung cancer (NSCLC). A Phase III study demonstrated that the drug significantly lowers the risk of relapse and death in patients following tumor resection. Alectinib is also approved for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer.
Alectinib was approved for medical use in Japan in 2014, the United States in 2015, Canada in 2016, Australia in 2017, the European Union in 2017, and the United Kingdom in 2021.
